Medicinal oxygen classification favours the specific medicines entry over the general gases entry, invalidating reassessment orders

Oxygen IP, manufactured under a drug licence and described as OXYGEN I.P., was treated as a medicinal product used in hospitals and treatment. Applying the common parlance, user and functional tests, the Court held that medicinal oxygen fell within the entry for medicines and pharmaceutical preparations, while the later entry for oxygen and other gases was only a general residual entry and could not displace the specific medicinal classification. The reassessment orders were therefore based on an erroneous tax classification and were set aside.

---

---

Issues: Whether oxygen IP or medicinal oxygen is classifiable under the entry for medicines and pharmaceutical preparations or under the entry for oxygen and other gases, and whether the reassessment orders based on the higher rate of tax could stand.

Analysis: Oxygen IP was manufactured under a drug licence issued under the Drugs and Cosmetics Act, 1940 and was shown in the licence as OXYGEN I.P. The Court treated it as a drug and a medicinal product used in hospitals and for treatment. Applying the common parlance, user and functional tests, the Court held that the commodity answers the description of medicines and pharmaceutical preparations in the earlier notification. The later entry for oxygen and other gases was held to be a general entry and, by its exclusion clause, could not cover a product already included in another notification. Since medicinal oxygen fell within the specific medicinal entry, it could not be taxed under the general gas entry. On that basis, the reassessment orders proceeded on an erroneous tax classification.

Conclusion: Oxygen IP or medicinal oxygen was taxable at 8% under the entry for medicines and pharmaceutical preparations and not at 12% under the entry for oxygen and other gases. The reassessment permission and reassessment orders were unsustainable and were set aside.

---